|Bid||6.00 x 800|
|Ask||17.00 x 900|
|Day's Range||6.26 - 6.70|
|52 Week Range||4.70 - 13.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! A look at the shareholders of Iterum Therapeutics plc (NASDAQ:ITRM)Read More...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...